UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

Charles the Securities England 2.200 v.							
(Amendment No.)*							
	Astria Therapeutics, Inc.						
	(Name of Issuer)						
	Common Stock, \$0.001 par value						
	(Title of Class of Securities)						
	04635X102						
	(CUSIP Number)						
	August 31, 2022						
	(Date of Event which Requires Filing of this Statement)						
Ch	eck the appropriate box to designate the rule pursuant to which this Schedule is filed:						
	Rule 13d-1(b)						
X	Rule 13d-1(c)						
	Rule 13d-1(d)						
*	The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.						
	The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the						

CUSIP No. 04635X102							
COSII NO							
1	NAMES OF REPORTING PERSONS						
	Vivo Opportunity, LLC						
	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)						
2	(a) \square						
	(b) □						
_	SEC USE ONLY						
3							
4	CITIZENSHIP OR PLACE OF ORGANIZATION						
7	Delaware						
			SOLE VOTING POWER				
NUMBE	-	5	1,000,000 ⁽¹⁾				
SHAR			SHARED VOTING POWER				
BENEFIC OWNEI		6					
	EACH REPORTING PERSON WITH		SOLE DISPOSITIVE POWER				
			1,000,000 (1)				
****			SHARED DISPOSITIVE POWER				
			0				
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON						
,	1,000,000 (1)						
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)						
10							
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)						
11	7.1 % (2)						
12	TYPE OF REPORTING PERSON (See Instructions)						
12	00						

- (1) The shares of common stock, \$0.001 par value (the "Common Stock") of Astria Therapeutics, Inc. (the "Issuer") are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P.
- (2) Based on 14,016,955 shares of Common Stock of the Issuer issued and outstanding as of the reporting date, which includes the sum of (i) 13,016,955 shares of Common Stock outstanding as of July 29, 2022, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on August 9, 2022, and (ii) 1,000,000 shares of Common Stock acquired by Vivo Opportunity Fund Holdings, L.P. in the at-the-market offering pursuant to the Issuer's Registration Statement on Form S-3 (File No. 333-264911), filed with the SEC on May 13, 2022.

Ітем 1.	(a)	Name of Issuer:			
		Astria Therapeutics, Inc.			
	(b)	Address of Issuer's Principal Executive Offices:			
		75 State Street, Suite 1400			
		Boston, Massachusetts, 02109			
Ітем 2.	(a)	Name of Person Filing:			
		Vivo Opportunity, LLC			
	(b)	Address of Principal Business Office or, if None, Residence:			
		192 Lytton Avenue, Palo Alto, CA 94301			
	(c) Citizenship:				
		Delaware limited liability company.			
	(d)	Title of Class of Securities:			
		Common Stock, par value \$0.001 per share			
	(e)	CUSIP Number:			
		4635X102			
Ітем 3.	IF THIS STATEMENT IS FILED PURSUA		§§ 240.13d-1(b), or 240.13d-2(b) or (c), Check Whether the Person Filing is a:		
	(a)	☐ Broker or dealer registered under	Section 15 of the Act.		
	(b)	☐ Bank as defined in Section 3(a)(6) of the Act.		
	(c)	☐ Insurance company as defined in	Section 3(a)(19) of the Act.		
	(d)	☐ Investment company registered to	under Section 8 of the Investment Company Act of 1940.		
	(e)	☐ An investment adviser in accorda	ance with § 240.13d-1(b)(1)(ii)(E);		
	(f)	☐ An employee benefit plan or end	owment fund in accordance with § 240.13d-1(b)(1)(ii)(F);		
	(g)	☐ A parent holding company or co	ntrol person in accordance with § 240.13d-1(b)(l)(ii)(G);		
	(h)	☐ A savings association as defined	in Section 3(b) of the Federal Deposit Insurance Act;		
	(i)	☐ A church plan that is excluded f Act;	from the definition of an investment company under Section 3(c)(14) of the Investment Company		
	(j)	☐ A non-U.S. institution in accorda	nnce with § 240.13d-1(b)(1)(ii)(J);		
	(k)	☐ Group, in accordance with § 240	.13d-1(b)(l)(ii)(K).		
	If fili	ng as a non-U.S. institution in accordance v	with § 240.13d-1(b)(1(ii)(j), please specify the type of institution:		
	Not A	applicable.			

ITEM 4. OWNERSHIP.

(a) Amount beneficially owned:

The 1,000,000 shares of Common Stock of the Issuer are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P. The voting members of Vivo Opportunity, LLC are Gaurav Aggarwal, Hongbo Lu, Kevin Dai, Frank Kung, and Michael Chang, none of whom has individual voting or investment power with respect to these shares and each of whom disclaims beneficial ownership of such shares.

(b) Percent of class:

7.1 %

(c) Number of shares as to which such person has:

- (i) Sole power to vote or to direct the vote: 1,000,000 shares
- (ii) Shared power to vote or to direct the vote: 0
- (iii) Sole power to dispose or to direct the disposition of: 1,000,000 shares
- (iv) Shared power to dispose of or to direct the disposition of: 0

Item 5. Ownership of Five Percent or Less of a Class.

Not Applicable.

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not Applicable.

ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON.

Not Applicable.

ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.

Not applicable.

ITEM 9. NOTICE OF DISSOLUTION OF GROUP.

Not applicable.

ITEM 10. CERTIFICATIONS.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a11.

SIGNATURE